152561-91-6
152561-91-6
Chemical Structure
Verapamil-d3
Synonym(s): (±)-Verapamil-d3; CP-16533-1-d3
- CAS No.: 152561-91-6
- Formula:C27H35D3N2O4
- Molecular Weight:457.62
InChIKey: SGTNSNPWRIOYBX-HPRDVNIFSA-N
SMILES: COC(C=C1CCN(C([2H])([2H])[2H])CCCC(C#N)(C2=CC(OC)=C(C=C2)OC)C(C)C)=C(C=C1)OC
Biological Activity: Verapamil-d3 ((±)-Verapamil-d3) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Verapamil-d3 | Verapamil-d3 ((±)-Verapamil-d3) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil (Standard) | 99.72% | Verapamil (Standard) is the analytical standard of Verapamil. This product is intended for research and analytical applications. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-Verapamil-d7 (hydrochloride) | (Rac)-Verapamil-d7 (hydrochloride) is the deuterium labeled (Rac)-Verapamil. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil-d6 | Verapamil-d6 ((±)-Verapamil-d6) is deuterium labeled Verapamil. Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil-d7 | Verapamil-d7 is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Verapamil | 99.88% | Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Gowarty JL, et al. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract. 2019 Apr;25(3):743-746. [Content Brief]
- [3]. Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21 Suppl 2:183S-189S. [Content Brief]
